临床神经外科杂志2024，Vol.21Issue(4)：442-447,6.DOI:10.3969/j.issn.1672-7770.2024.04.016
胶质母细胞瘤相关药物治疗的研究进展
Research progress on drug therapy for glioblastoma
摘要
Abstract
Glioblastoma(GBM)is a high-grade malignant tumor originating from intracranial glia,with a high recurrence rate and poor prognosis.The standard treatment mode is surgical resection of tumor combined with radiotherapy and chemotherapy,but the effect is greatly reduced due to the limitation of Blood-brain barrier and the mechanism of drug resistance to chemotherapy drugs.In recent years,according to the continuous research on the effect and drug resistance mechanism of the existing Temozolomide,Nitroso,Bevacizumab and other commonly used anti GBM drugs,a variety of effective combination therapies have been found.In addition,exploring new methods in the field of nanotechnology has had a significant impact on the process of GBM.This article reviews the latest research progress on the resistance mechanisms,effective combination therapy,and other strategies to improve efficacy of commonly used anti GBM chemotherapy drugs.关键词
胶质母细胞瘤/抗癌药物/耐药/联合治疗/纳米技术Key words
glioblastoma/chemotherapy drugs/drug resistance/combined treatment/nanotechnology分类
医药卫生引用本文复制引用
王一帆,王春红,郭艾洁,吉宏明..胶质母细胞瘤相关药物治疗的研究进展[J].临床神经外科杂志,2024,21(4):442-447,6.基金项目
山西省基础研究计划项目(20210302124380) （20210302124380）
山西省基础研究计划项目(202103021224386) （202103021224386）
